SPK-843(SPK-843) - _专利_临床

概要

基本信息

药物类型

化学药

别名

Amcipatricin、SPA-A-753 (Diaspartate salt)

+ [6]

靶点-

作用方式

调节剂

作用机制

细胞膜调节剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症-

非在研适应症

曲霉菌病隐球菌病肺部真菌感染+ [1]

原研机构

Società Prodotti Antibiotici SpA

在研机构-

非在研机构

Società Prodotti Antibiotici SpAPRO.PARTS SRL

Kaken Pharmaceutical Co., Ltd.

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C67H103N5O19

InChIKeyUJGVOBAKMNJQEV-WHMYMHFRSA-N

CAS号143483-67-4

关联

2

项与 SPK-843 相关的临床试验

NCT01125644

/ Unknown status临床3期

Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study

Recruitment of at least 10 adult patients (men and women) among individuals affected and admitted to the hospitals identified for the clinical study. All patients shall be between 18 and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's visits (day 1,3,7,10,14,21, and 28).

开始日期2010-05-01

申办/合作机构

PRO.PARTS SRL

EUCTR2009-014652-30-IT

/ Not yet recruitingN/AIIT

Efficacy, safety and pharmacokinetics of SPK-843 in the treatment of pulmonary mycosis.Phase III Open clinical study - ND

开始日期2009-10-29

申办/合作机构-

100 项与 SPK-843 相关的临床结果

登录后查看更多信息

100 项与 SPK-843 相关的转化医学

登录后查看更多信息

100 项与 SPK-843 相关的专利（医药）

登录后查看更多信息

16

项与 SPK-843 相关的文献（医药）

2008-05-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Efficacy of SPK-843, a Novel Polyene Antifungal, in a Murine Model of Systemic Cryptococcosis

2区 · 医学

Article

作者: Yanagihara, Kazunori ; Tashiro, Takayoshi ; Seki, Masafumi ; Izumikawa, Koichi ; Miyazaki, Yoshitsugu ; Yamamoto, Yoshihiro ; Kohno, Shigeru ; Senda, Hisato ; Kobayashi, Tsutomu ; Kakeya, Hiroshi

ABSTRACT SPK-843, a new polyene antifungal, possessed efficacy in a murine model of systemic infection caused by Cryptococcus neoformans . The administration of 4.0 mg/kg SPK-843 led to better survival prolongation and fungal reduction than those observed with the administration of 0.7 mg/kg amphotericin B and 80 mg/kg fluconazole ( P < 0.001), without histopathological renal changes.

2008-05-01·Antimicrobial Agents and Chemotherapy2区 · 医学

Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis

2区 · 医学

Article

作者: Seki, Masafumi ; Tashiro, Takayoshi ; Yamamoto, Yoshihiro ; Izumikawa, Koichi ; Yanagihara, Kazunori ; Miyazaki, Yoshitsugu ; Kohno, Shigeru ; Senda, Hisato ; Kobayashi, Tsutomu ; Kakeya, Hiroshi

ABSTRACTSPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

2005-08-01·Current opinion in investigational drugs (London, England : 2000)

SPK-843 (Aparts/Kaken).

Review

作者: Kasanah, Noer ; Hamann, Mark T

SPK-843 is a water-soluble antibiotic under co-development by Aparts and Kaken for the potential treatment of systemic fungal infections. By November 2004, SPK-843 was in phase II trials for systemic mycosis.

100 项与 SPK-843 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12333

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺部真菌感染	临床3期	意大利	PRO.PARTS SRL	2010-05-01
曲霉菌病	临床3期	-	Kaken Pharmaceutical Co., Ltd.	-
曲霉菌病	临床3期	-	Società Prodotti Antibiotici SpA	-
曲霉菌病	临床3期	-	Società Prodotti Antibiotici SpA	-
曲霉菌病	临床3期	-	Kaken Pharmaceutical Co., Ltd.	-
隐球菌病	临床3期	-	Kaken Pharmaceutical Co., Ltd.	-
隐球菌病	临床3期	-	Kaken Pharmaceutical Co., Ltd.	-
隐球菌病	临床3期	-	Società Prodotti Antibiotici SpA	-
隐球菌病	临床3期	-	Società Prodotti Antibiotici SpA	-
真菌病	临床3期	日本	Kaken Pharmaceutical Co., Ltd.	-